Nanotechnology-Enhanced Delivery and Bioactivity of Dietary Flavonoids: Overcoming Bioavailability Barriers for Targeted Antimicrobial and Antiviral Therapies-A Comprehensive Review Authors: Sayed M Saleh, Riaz A Khan, Lotfi M Aroua, Hamdoon A Mohammed Published: 2026 ABSTRACT AbstractFlavonoids are a class of naturally occurring compounds primarily present in plants and are also part of some of the byproducts of certain insects’ metabolites, such as propolis. Given the growing burden of infectious diseases and the urgent need for more effective therapeutic options, advancing flavonoid-based interventions is of prime clinical significance. These compounds possess unique chemical characteristics and exhibit pronounced biological activities, including antioxidant, anti-inflammatory, antiviral, immunomodulatory, and antibacterial, making the class a potent contender for managing certain health concerns, including health issues arising out of pandemic situations. However, limitations involving low aqueous solubility, less oral bioavailability, fast metabolism, structural instability, and limited tissue targeting have restricted their clinical applications as therapeutic agents. In this context, nanotechnology offers feasible remediation to overcome these shortcomings by enhancing solubility, absorption, transitional stability, and controlled and sustained release, as well as enhanced on-site bioavailability and effective therapeutic control that transforms into increased biological activity. The current overview encompasses literature information collected from the database platforms of PubMed, Google Scholar, ScienceDirect, Scopus, and Web of Science, with the particular focus on studies published in the last decade (2015–2025). Information relating to nanotechnology-enabled flavonoid delivery covering polymeric and lipid nanoencapsulates, nanoemulsions, nanocrystals, liposomes, solid lipid nanoparticles (SLNPs), nanostructured lipid carriers, metallic NPs, and nanofibers has been assessed and analyzed. These nanosystems and complex delivery platforms have demonstrated improvements in flavonoids’ solubility, cellular uptake, circulation time, and stability and have facilitated targeted/sustained release of the payload to the sites of action, ie, infections and inflammations. Additionally, the environmentally benign green synthetic approaches for constituent flavonoids and their formulations emphasized the roles in enhancing the safety, toxicity reduction, stability, and sustainable use. Although preclinical studies have produced encouraging therapeutic results, the clinical translation requires standardized flavonoid sources, reproducible protocols, scaling-up formulation methods, comprehensive physicochemical characterization, toxicity evaluations, and pharmacokinetic studies with rigorously designed clinical trials. Introduction Flavonoids are the naturally occurring organic molecules synthesized as secondary plant metabolites through the shikimic acid pathway, which have exhibited a C6-C3-C6 phenyl propanoid ringed chemical structure-skeleton, and are abundant in a variety of plants, shrubs, herbs, fruits, vegetables, flowers, and other parts of the plants, including roots.1,2 The flavonoid compounds have shown diverse structural variations, including several aglyconic and glyconic forms. Some of these compounds exhibited strong pharmacological and other biological activities, including antioxidants, hepatoprotective, cardiotonic, antipyretic, antidiabetic, anti-inflammatory, antimicrobial, anti-Alzheimer’s, anti-atherosclerotic, antimutagenic, and anticancer activities.3,4 The therapeutic value is demonstrated by their structural novelties, which modulate biochemical pathways and enzyme functions, eg, phosphoinositide 3-kinase, cyclo-oxygenase (COX), xanthine oxidase (XO), and lipoxygenase to remediate diseased conditions. The role of flavonoids in human health, well-being, and nutrition is highly significant, and the flavonoid compounds have contributed in various different ways to food, therapeutics, and cosmetics applications.5,6 The flavonoids’ abundance, mainly in the higher plants, with structural complexities of the aglycone and glycone structural parts have been corroborated by the evolved plants enzyme systems’ presence and their functional prowess,7 with the ability to produce the secondary metabolites of various structural variations through the common biogenesis together with the aberrant biogenesis in response to external elicitators producing the differentiations in positions and quantity (degree) of hydroxylation, the degree of polymerization,8 inter-structure conjugation, substitutions and glycone variations of structure and attachments through the oxygen and carbon intermediates,9,10 which demonstrated the versatility of the natural biogenesis of these class of compounds, that are categorized as flavone, flavanone, flavonol, isoflavone, pterocarpanoid, rotenone, and other structural variations within the aglycone structures and glycine part variabilities observed in methoxy, acetoxy, prenyl, extended prenyl, methylene dioxy constituents in aglycone and mono and multi glyconic structures.11,12 Also, acetylation and methylation have produced a wide variety of functional and bioactive compounds, thereby enriching the natural abundance of the flavonoids in particular and natural products in general on a very large scale in nature.12,13 The flavonoid distribution in plant families, their biogenetic origins, reported biosynthetic pathways, structural variations, and bioactivity needs further attention. A critical in-depth look for biomechanistic details, efficiency output of the bioactivity based on epidemiological evidence, bioavailability in the human body, in vitro and in vivo routing feasibilities, and delivery options towards phytoproducts development is warranted. A large number of angiospermic plant families produce the flavonoids through injunction of the polyketide (shikimate) and acetate pathways. The shikimate pathway generates p-coumaroyl-CoA (via phenylalanine and cinnamic acid intermediates), while the acetate (malonyl-CoA) pathway provides malonyl-CoA. Chalcone synthase (CHS) catalyzes the condensation of one p-coumaroyl-CoA molecule with three malonyl-CoA molecules to form the chalcone, the central precursor in the flavonoid biosynthesis (Figure 1).13,14 Phenylalanine is the initial amino acid source-product derived from shikimate, which generates cinnamic acid through phenylalanine ammonia lyase (PAL) catalysis. The formed flavonoids accumulate in the plant vacuoles, and structurally, based on the degree of oxidation/oxygen presence, are found variedly different as chemical structure-specified classes as flavonols, flavones, isoflavones, anthocyanidins, flavanones, flavanols, and chalcones (Figure 2). Figure 1Plausible biosynthetic pathway of flavonoids.The diagram illustrates the flavonoid biosynthesis pathway. It begins with the combination of malonyl-CoA and coumaroyl-CoA catalyzed by chalcone synthase to form chalcone. Chalcone is then converted to dihydroflavone, which can be transformed into isoflavone by isoflavone synthase or into flavone by flavone synthase. Dihydroflavonol is formed from dihydroflavone via flavanone 3-hydroxylase. Dihydroflavonol can be reduced by dihydroflavonol 4-reductase to form flavan-3,4-diol, which is further processed by leucoanthocyanidin reductase to produce flavan-3-ol or by leucoanthocyanidin dioxygenase to form anthocyanidin. Flavonol is synthesized from dihydroflavonol by flavonol synthase. The diagram also includes a visual representation of a flower, indicating the natural context of flavonoid production.Flavonoids form from malonyl-CoA and coumaroyl-CoA via chalcone in biosynthesis pathway. Figure 2Major chemical classes of flavonoids.The figure demonstrates the structural diversity among flavonoid compounds by showing differences in their core skeletons. Flavone and isoflavone both possess a ketone group at the C4 position, but the B-ring is attached at C2 in flavone and at C3 in isoflavone. Flavonol is structurally similar to flavone but includes an additional hydroxyl group at the C3 position. Flavanone and flavanonol both have a saturated (single) bond between C2 and C3, with flavanonol also featuring a hydroxyl group at C3, distinguishing it from flavanone. Flavanol (often called catechin) lacks the ketone group at C4 but has both a saturated C2–C3 bond and a hydroxyl group at C3. These variations in double/single bonds, functional groups, and ring attachment sites underlie the chemical and biological diversity of flavonoids.Structures of flavone, isoflavone, flavonol, flavanonol, flavanol and flavanone. Plausible biosynthetic pathway of flavonoids. Major chemical classes of flavonoids. The flavonoids are crucial for the survival of plants, animals, and humans. The flavonoid compounds play numerous well-defined roles in several biological processes in the plants, and in the biochemical systems, the cellular pathways and enzymes of the animal and plants kingdom, eliciting various biological activities.15 Plant growth, development, diversification, fruiting, and ripening, the resistance to biotic and abiotic factors, and the defenses against viruses, fungi, and bacteria are also managed by various flavonoid molecules, that are present in the plants and taken by humans. Among the major pharmacological activities, antioxidant, anti-inflammation, anti-cancer, cardiovascular, and neurological activities, as well as resistance to several other diseases and malfunctioning physiological processes, are worth mentioning.16 This outreach and properties of flavonoids have provided them with enough medicinal value and profound economic importance.15,17 Moreover, on the bioactivities front, a number of flavonoids have shown diverse bioactivities, wherein the anti-inflammatory activity has been found to be mediated by proinflammatory factors and substances, such as nitric oxide, ROS (Reactive Oxygen Species),18 prostaglandins, cyclooxygenase, nitric oxide synthase (NOS), and cytokines, which have been observed to be inhibited by several flavonoids that suppresses their inter-dependent enzymatic activities.19 Several flavonoids, ie, catechin, quercetin, apigenin, rutin, and naringenin, have been reported to also possess hepatoprotective activity. These flavonoids interact with low-density lipoproteins, smooth muscles, platelets, and monocytes. The actions of flavonoids against atherosclerosis, thromboxane A2, PAF, and serotonin production have received considerable attention.20 The quercetin and kaempferol derivatives are known to inhibit platelet activity.21 The intricate involvement of flavonoids with extracellular soluble proteins and the bacterial cell wall have conferred antimicrobial properties to these compounds.22 Rutin, a flavonoid anti-infective and anti-viral compound, has shown mild anti-tuberculosis activity.23 The flavonoids have been, to some extent, active in neurodegenerative disorders, eg, Alzheimer’s and Parkinson’s diseases also. Flavonoids’ inhibition of xanthine oxidase, aldose reductase, Ca2+ ATPase, COX, phosphodiesterase, and lipoxygenase is well known for its role in neurodegenerative disorders.4 The anticancer properties of certain diets have been linked to their high flavonoid contents.24 The flavonoid quercetin has shown growth-inhibitory effects against some of the malignant tumor cell lines and has also arrested the proliferating lymphoid cell cycles. The flavonoid contents-rich tea consumption was associated with better bone health in elderly people.25 Moreover, some flavonoid components have also been reported to combat microbial activity and reverse antibiotic resistance, thereby enhancing the overall efficacy of the drug. Notwithstanding the evidence-based therapeutic efficacy of the flavonoids, the clinical implementation for various therapeutic segments’ applications of these compounds remains highly confined, and with limited scope, owing to these compounds various chemo-biological and pharmaceutical factors, such as the insolubility of the flavonoids in aqueous media, their limited bioavailability at the site of action, low transitional stability in systemic circulation, shortened biological half-life, the fast metabolic breakdown and their absence of specificity regarding the target organ(s). These limitations have led to declines in their overall efficiency as free and pure flavonoids, together with their impeding applications in clinical settings.26,27 In order to deal with these obstacles, innovative methods need be employed to improve the flavonoids’ solubility, stability, enhancements of their bioactivity and delivery effectiveness, as well as their continued and sustained release. Since nanotechnology has the potential and has provided a variety of specific nanosystems’ that surmount the above-mentioned hurdles, the technique has found favors with formulation scientists. The nano-enabled products have led to efficient advancement in therapeutic applications of flavonoids.28,29 For example, exhaustive work on polymeric nanoparticles (NPs) and liposomes have accomplished to achieve the enhanced solubility of flavonoids in aqueous media together with lengthening their transitional stability, overall resident time without degradation, and it has boosted-up required persistence in circulation, while the inorganic nanocarriers, and metal-organic frameworks (MOFs) provided a high payload carrying capacity in an adjustable and sustained release pattern.30 Besides these advantages, the surface-modified nanomaterials, formed as part of complex and multi-layered nano-systems, also aimed to improve bioavailability, reduce the drug’s adverse reactions, and allowed for the directed and site-specific delivery of the flavonoid contents. Eventually, incorporating flavonoids within and at nanotechnology‑based platforms provided several potential avenues and feasible approaches for restructuring the ultimate, tailor-made capabilities and specifications-driven formulations for the therapeutic utilizations.31 Flavonoid-Mediated Metal Nanoparticles Eco-Friendly Synthesis The eco-friendly synthesis of metal‑organic NPs utilizing the flavonoids and flavonoid-laden plant’s extracts has become a viable approach for creating biocompatible nanomaterials under moderate and environmentally benign procedures.32–34 Flavonoids are characterized by presence of their numerous phenolic hydroxyl groups and conjugated aromatic ring system, which endows them with natural reducing strength and significant affinity for metal surfaces, thereby concurrently allowing these compounds to serve as reducing, capping, and stabilizing agents.35,36 In conventional methods, solutions of metal salts such as silver nitrate, chloroauric acid, copper salts, or selenium precursors are mixed with purified flavonoids or flavonoid-rich compounded plant extracts; the flavonoid molecules provide electrons to metal ions, producing zero-valent nuclei that evolve into NPs, while oxidized flavonoid species attaches itself to the metal surface to establish a stabilizing organic corona.37,38 This unified reduction-capping strategy circumvents the requirement for potent chemical reductants and use of a separate synthetic surfactants, in accordance with the ideals of green and sustainable nanotechnology procedure.39 Concurrently, the chemical identity and concentration of the flavonoid, the metal chosen, and the reaction conditions (pH, temperature, time) also profoundly impact the size, form, crystallinity, and surface properties of the produced NPs, which in turn influences the antimicrobial, antioxidant, sensing, and catalytic capabilities of the nano-products thus synthesized.40,41 In order to provide a comparative summary, the ensuing table delineates representative nanosystems, focusing on the metals involved, the natural compounds used, and the principal features of the NPs produced, together with their usual applications, and significant references that chronicles the sustainable preparative techniques as part of a brief description (Table 1). Table 1Metal NPs Green Synthesis Mediated by Flavonoids and Related Natural CompoundsMetal TypeFlavonoid CompoundNPs FeaturesBio-Based ApplicationsRef.Silver (Ag)Quercetin and Ocimum sanctum (Tulsi) leaf extractSpherical AgNPs with uniform size distribution; strong surface plasmon resonance; good colloidal stability under optimized pH and temperature.Antibacterial activity against Gram-negative bacteria (eg, E. coli); potential use in antimicrobial coatings and wound dressings.[42]Silver (Ag)Various medicinal plants; mixed polyphenolsColloidal AgNPs with size typically in the 10–50 nm range; morphology dependent on extract composition.Broad-spectrum antimicrobial agents; antioxidant and anti-inflammatory water disinfection.[43]Silver (Ag)Hesperidin, naringin, diosminAgNPs synthesized with controlled size and moderate polydispersity; cytotoxicity profile depends on flavonoid used.Antibacterial agents against selected Gram-positive and Gram-negative strains; potential cytotoxic activity against cancer cell lines with tunable selectivity.[44]Gold (Au)TricetinSpherical AuNPs with average size around 10–20 nm; hydroxyl and carbonyl groups of tricetin involved in reduction and capping; good colloidal stability at mildly alkaline pH.Broad-spectrum antibacterial activity against respiratory pathogens; potential nanomedicine for treating infections with good biocompatibility in human dermal fibroblasts.[45]Silver-selenium (Ag-Se)Flavonoid rutin (rutin-rich extracts)Bimetallic or core-shell Ag-Se nanoparticles; nanoscale size with enhanced surface properties; rutin acts as both reducer and stabilizer.Eradication of oral and dental pathogens; potential applications in dental materials and antimicrobial oral care formulations.[46]Various metals (Ag, Au, Cu and others)Mixed flavonoids and polyphenols from plant extractsNanoparticles with size and morphology dependent on extract composition and conditions.Antimicrobial nanomaterials targeting multidrug-resistant bacteria; antioxidant systems; potential use in food packaging[47] Table 1Metal NPs Green Synthesis Mediated by Flavonoids and Related Natural CompoundsMetal TypeFlavonoid CompoundNPs FeaturesBio-Based ApplicationsRef.Silver (Ag)Quercetin and Ocimum sanctum (Tulsi) leaf extractSpherical AgNPs with uniform size distribution; strong surface plasmon resonance; good colloidal stability under optimized pH and temperature.Antibacterial activity against Gram-negative bacteria (eg, E. coli); potential use in antimicrobial coatings and wound dressings.[42]Silver (Ag)Various medicinal plants; mixed polyphenolsColloidal AgNPs with size typically in the 10–50 nm range; morphology dependent on extract composition.Broad-spectrum antimicrobial agents; antioxidant and anti-inflammatory water disinfection.[43]Silver (Ag)Hesperidin, naringin, diosminAgNPs synthesized with controlled size and moderate polydispersity; cytotoxicity profile depends on flavonoid used.Antibacterial agents against selected Gram-positive and Gram-negative strains; potential cytotoxic activity against cancer cell lines with tunable selectivity.[44]Gold (Au)TricetinSpherical AuNPs with average size around 10–20 nm; hydroxyl and carbonyl groups of tricetin involved in reduction and capping; good colloidal stability at mildly alkaline pH.Broad-spectrum antibacterial activity against respiratory pathogens; potential nanomedicine for treating infections with good biocompatibility in human dermal fibroblasts.[45]Silver-selenium (Ag-Se)Flavonoid rutin (rutin-rich extracts)Bimetallic or core-shell Ag-Se nanoparticles; nanoscale size with enhanced surface properties; rutin acts as both reducer and stabilizer.Eradication of oral and dental pathogens; potential applications in dental materials and antimicrobial oral care formulations.[46]Various metals (Ag, Au, Cu and others)Mixed flavonoids and polyphenols from plant extractsNanoparticles with size and morphology dependent on extract composition and conditions.Antimicrobial nanomaterials targeting multidrug-resistant bacteria; antioxidant systems; potential use in food packaging[47] Metal NPs Green Synthesis Mediated by Flavonoids and Related Natural Compounds Nanocarrier Platforms for Flavonoid Delivery In this context, nanocarrier-based delivery systems have emerged as potent tools for overcoming the significant pharmaceutical obstacles that impede the effective clinical application of the flavonoids. A required specifications led, well designed and developed nanocarrier platform has the potential to offer an effective way for better formulation and delivery to overcome the inherent shortcomings of the flavonoids molecular specifications that obstruct the effective therapeutic outcomes. The rationale behind the selection of specific systems for antibacterial, antiviral, vaccine, or pandemic-related interventions through nanotechnology lies in its ability to provide the better delivery vehicle at nano meter scale dimensions, capability to encapsulate under metal and polymeric core, and conjugate different types of scaffolds to alter enhanced solubility, better stability, increased bioactivity and safety. A number of nanotechnical platforms are perfectly matched depending upon the requirements of the delivery mode and routes, dose-quantity requirements, continuous, sustained and chronological operability of the end-product formulation, specifics of the site of action, products and formulation stability requirements, metabolic concerns, and safety issues. One of the most extensively investigated platforms for the delivery of flavonoids is the lipid-based nanocarriers. This category encompasses nanoemulsions, SLNPs, liposomes, and nanostructured lipid carriers.48 Thin-film hydration, high-pressure homogenization, microfluidization, solvent injection, and melt emulsification are among the most common methods used to prepare these nano-systems. The lipid matrix safeguards the sensitive compounds from metabolic degradation, oral route nuisances, oxidation and hydrolysis, while the amphiphilic architecture enables the incorporation of both lipophilic and hydrophilic flavonoids.49 The lipid-based systems also increase oral bioavailability by improving gastrointestinal tract (GIT) stability, thereby facilitating the lymphatic transport, and enhancing the solubility and product passage through the customized particle size, surface charge, and lipid composition. Furthermore, these carriers provide a choice of administration routes, including oral, parenteral, topical, and mucosal delivery. This is especially pertinent enough for flavonoid-based formulations interventions in a variety of clinical settings and also for the tough pandemic situations of robust product and its delivery to achieve better and full therapeutic outcome per dose.50,51 Another significant platform for the delivery of flavonoids is the polymeric nanocarriers. Natural polymers, such as alginate and chitosan, as well as biodegradable synthetic polymers as PLGA, PLA, and PCL, can be engineered into nanofibers, micelles, nanogels, nanocapsules and NPs.31,52,53 Several preparatory methods are employed to prepare the nanoformulations that include ionotropic gelation, assisted encapsulation, molecular conjugation, self-assembly of amphiphilic block copolymers, neutral and neutralized polymers attachment and encapsulation through non-gel cross-linking, interfacial polymerization, nanoprecipitation, emulsification, solvent film saturation and evaporation, and spray-drying, etc. These systems enable the modulation of the drug release kinetics from instant to sustained through providing precise control over particle size, surface characteristics, and degradation pattern. It is plausible to accomplish tissue- and cell-specific delivery by functionalizing the polymeric nanocarriers with the attached or covered-up targeting ligands, which prolongs mucosal residence time, and protects flavonoids from acidic and enzymatic degradation in the GIT.54,55 Simultaneously, the translation of these formulations to clinical use needs to take into account the factors of residual solvent, polymer-related toxicity, product stability, effectiveness, outreach, and the existing regulatory complexity. The inorganic and metal-based nanocarriers provide unique sets of functionalities for the delivery of flavonoids. Through templated assembly, chemical and green reduction routes, and the sol-gel processes, hybrid nano-bio interfaces, metal and metal‑oxide NPs (including gold and silver, and iron and zinc oxides), and mesoporous silica NPs have been synthesized.40 The subsequent surface functionalization with silanes, polymers, and other biomolecules of plants and animal origins (chitosan, alginate, albumin, etc.) can be performed. The high surface area and extended molecular frameworks of these polymers facilitate the high pay-loading of flavonoids, while the tunable pore size and surface chemistry enables precise control over adsorption, release, and protection in the face of challenging physiological environmental conditions.56 Furthermore, the theranostic applications are also enabled by the optical, electronic, or magnetic properties of the specific inorganic carriers, which enables the combination of imaging well as triggered release of the flavonoid pay-load with smooth delivery.57 Notwithstanding, the robust and precisely designed development of these systems is still deeply rooted in the concerns of long-term bio-persistence, potential unwanted accumulation, and comprehensive toxicological evaluations. The next strategic platform for flavonoid nanodelivery is nanocrystals and carrier-free systems. Drug nanocrystals are crystalline particles that are nanosized and primarily composed of the drug itself, ie, flavonoids in this case. These products are stabilized by minimal quantities of surfactants and polymers, and are produced through media milling, high-pressure homogenization, and antisolvent precipitations.58,59 The nanocrystals substantially improve the apparent solubility and oral absorption of the poorly soluble flavonoids by significantly increasing their surface area and dissolution rate. This phenomena is achieved while maintaining a relatively simple excipient profile that is compatible with the solid and liquid dosage forms.51,60 Carrier-free self-assembled flavonoid NPs further reduces formulation complexity by utilizing the intrinsic amphiphilicity and intermolecular interactions of specific flavonoids to spontaneously form nanoscale aggregates.61 These systems are particularly effective when solubility is the primary obstacle; however, they are susceptible to physical instability, aggregation, and crystal growth, which necessitate a well-thought, pre-designed, meticulous formulation optimization, which is a desired step of the process.62 Nanotechnical Applications in Delivery of Natural Compounds: Concepts and Benefits The flavonoid bioactivity has generated widespread interest in their therapeutic applications, consequent to clinical evaluation of the feasible, robust, leak and degradation-proof delivery of flavonoids. Notwithstanding, the poor aqueous media solubility, strong lipophilic property, and low partition coefficients of certain flavonoid compounds have made their formulation and delivery challenging tough tasks. The low oral bioavailability, rapid metabolism, and short biological half-life have hindered the flavonoids-based drug development since the therapeutic efficacy of the flavonoid compounds is this way compromised. Nonetheless, the formulation strategies’ expansion into nanomedicine format have opened the developmental avenues for better products, their renewed bioactivity testings and dose size determinations, which have contributed to better therapeutic outcomes of the flavonoid class of compounds. The nanoformulation strategy is known for efficient delivery, enhanced solubility, improved lipophilicity, and adequate bioavailability. The nano formulation is also known to better achieve topical delivery, sustained and continuous delivery at a desired, stable dose rate to various, as well as designated sites at fixed times in a chronological fashion, that is supplemented with the ability to cross certain biological barriers. The nanoformulations have also provided stability of the deliverables, protection against payload degradation during transit, improved pharmacokinetics, new avenues for the design of smart and stealth nanocarriers, and various internal and external stimuli-responsive formulations, including magnetic and hyperthermia-based nanoformulation preparations, if required. Newer delivery options through AI-derived design have also emerged. Sustainable and environmentally benign formulations design for bulk quantities preparation of deliverables is also possible. The nanotechnological potential of flavonoid formulations has also opened the door to improved patient compliance, and resultant therapeutic efficacy. The pre-clinical and clinical evaluations of a larger number of flavonoids have been made possible by transformative nanotechnology-based formulation strategies, which have appeared over time. The preferred nanoformulation strategies have included nanoencapsulation, liposomal delivery, SLNPs, biodegradable and natural and synthetic polymer-based NPs, nanoemulsions, silica nanoparticle-loaded materials, and nanoscale micellar systems, together with site-directed, enzyme, and other ligand-entailed nanosystems for delivery. Physicochemical and Pharmacokinetics Challenges Flavonoids, despite their immense therapeutic potential, have not been fully clinically translated as viable pharmaceutical agents with significant pharmacological outcomes. The flavonoids-based drug development has been marred by various physicochemical and pharmacokinetic hurdles arising out of the flavonoid structures’ properties, dimensions, and framework. The poor aqueous solubility, low oral bioavailability, extensive first-pass metabolism, chemical instability under physiological conditions, and complex interactions with efflux transporters and metabolic enzymes are some of the factors limiting the full utilization of flavonoids towards drug development.63,64 The challenges related to high plasma protein binding, inter-individual variability mediated by gut microbiota, the potential for toxicity at supraphysiological doses, and clinically relevant drug–drug interactions are also the limiting factors in achieving the drug developmental goals. Understanding these limitations is crucial towards the rational design of the flavonoid-based end products for effective, safe, and unhindered delivery through various delivery platforms, which essentially require structural modifications and semi-synthetic transformation, if need be, to harness the full clinical potential of the flavonoids through their formulated dosage forms. The structural specifications of the essential C6-C3-C6 framework with oxidation, hydroxylation, methylation and prenylation patterns, the substitution on the C ring, have opened certain level of susceptibility for flavonoids structural transformation through conjugation, semi-synthesis, ligand binding for fine tuning the physicochemical and pharmaceutical properties through their basic structures of major flavonoids subgroups, namely flavones, flavonols, flavanones, flavanols (catechins), isoflavones, and anthocyanins.65 For decades, they have attracted significant attention in the fields of nutrition and pharmacology due to their diverse health-promoting effects.66 Epidemiological studies have consistently linked high dietary intake of flavonoids with reduced risk of chronic diseases, including cardiovascular, neurodegenerative disorders, type 2 diabetes, and various types of cancers.67,68 In vitro and in vivo experimental models have demonstrated the potent antioxidant capacity, ability to modulate key cellular signaling pathways, and anti-inflammatory mechanisms of the flavonoids class of compounds.20,69 However, a stark discrepancy often exists between the promising in vitro bioactivity of the flavonoids and their in vivo efficacy under animal models and clinical evaluation conditions.70 This “translational gap” arising out of flavonoids poor solubility, low bioavailability, rapid and extensive metabolism, chemical instability, and rapid elimination is primarily attributed to a number of pharmacokinetic and physicochemical challenges that limit the systemic exposure and accumulation of the flavonoid drugs at the target tissues.71 Physicochemical Challenges Poor Aqueous Solubility Among the most fundamental challenges in pharmacological application of flavonoids is their inherently poor aqueous solubility.72 The lipophilic nature of the flavonoid aglycone framework is characterized by multiple aromatic rings, presence of methoxyl and prenyl groups together with various positional substitutions of hydroxyl groups on the aromatic rings, some of which also forms intramolecular hydrogen bonding and the structure is finally rendered insoluble in aqueous media and biological fluids.27 On the other hand, the glycosylation (attachment of saccharide moieties), which is the predominant form of flavonoid structural entities present in nature, generally increases the water solubility as compared to their aglycone counterparts, is often still insufficient for optimal pharmaceutical formulation, absorption and delivery.73 The poor solubility translates into low dissolution of the compound in the gastrointestinal tract (GIT, which is a rate-determining step for oral absorption in accordance with the Noyes-Whitney equation. According to the Biopharmaceutics Classification System (BCS), certain bioactive flavonoids, such as quercetin, naringenin, and luteolin, are classified as Class II (low solubility, high permeability), or Class IV (low solubility, low permeability) compounds.74 This poor solubility significantly restricts the concentration gradient driving the passive diffusion across the intestinal epithelium, thereby leading to erratic and limited oral bioavailability.75 This challenge is further compounded by the fact that many of the flavonoids exhibit crystal polymorphism, and their dissolution behavior varies depending on the crystalline form of the compound present in the formulation. Chemical Instability Flavonoids are highly susceptible to chemical degradation under various physiological conditions, thereupon further complicating their pharmacological applications.76 The compounds’ stability is profoundly influenced by factors such as pH, temperature, light exposure, the presence of oxygen, metal ions and metal ion catalysis.77 The catechol (ortho-dihydroxy) structural moiety present in several flavonoids (eg, quercetin, luteolin, catechins) is vulnerable to oxidative degradation, thereby leading to formation of quinones and their subsequent polymerization products. In the context of oral administration, the varying pH medium along the GIT poses a significant challenge. While many flavonoids exhibit relative stability in the acidic environment of the stomach (pH 1.5–3.5), they undergo rapid degradation in the neutral to slightly alkaline pH of the small intestine (pH 6.8–7.4) and the colon (pH 7.0–8.0).78 For instance, catechins from green tea are known to be highly unstable at physiological pH, undergoing autooxidation, epimerization, and ring-opening reactions.79 Similarly, the anthocyanins are remarkably sensitive to pH changes, existing in their stable red flavylium cation formed only at acidic pH and transformed into colorless carbinol and chalcone forms at neutral pH.80 This pH-dependent degradation reduces the quantity of intact flavonoid available for absorption at the primary sites of uptake in the GIT especially in the small intestine. Pharmacokinetics Challenges Low Bioavailability The combining factors of low aqueous solubility, structure’s chemical instability through oxidation and other degradations, limited GIT permeation, and extensive metabolism result in notoriously low bioavailability of flavonoid compounds through oral route, which is often reported to be under 5% for many compounds and at times reaching to be as low as 1–2% is root cause of several delivery based hurdles in development of flavonoids-based drugs.81 The bioavailability refers to the fraction of an administered dose of an unchanged drug that reaches the systemic circulation and is available to exert its pharmacological effect.82 This low bioavailability of flavonoids means that achieving therapeutically relevant plasma concentrations, effective biological half-life of the product, and target tissue accumulation through oral administration is extremely difficult.83 This represented a fundamental inconsistency in flavonoids pharmacology. The compounds that demonstrated remarkable potency in cell-based assays often failed to achieve sufficient concentration under in vivo conditions to replicate these effects in the clinical settings. Figure 3 illustrates a breakdown of the four primary physiological stages limiting the flavonoid absorption, gastrointestinal degradation, intestinal membrane efflux, hepatic first-pass metabolism, and rapid systemic clearance. Figure 3Comprehensive schematic of the pharmacokinetic barriers and metabolic pathways responsible for low orally routed dietary flavonoids bioavailability throughout the human GIT and systemic condition.The diagram outlines flavonoid absorption, metabolism and elimination. It starts with consuming flavonoid-rich foods, highlighting quercetin′s structure. In the stomach (pH 1-3), enzymatic degradation occurs. In the small intestine (pH 6-7.5), solubility and stability issues arise, leading to poor absorption. Glycosides are degraded by microbiota, with limited passive diffusion. Efflux transporters (BCRP, MRPs) restrict blood/lymph entry. In enterocytes, phase II metabolism (glucuronidation, sulfation, methylation) occurs, reducing active aglycone via first-pass metabolism. Low plasma concentration results from poor absorption, extensive metabolism and rapid elimination. Distribution involves high plasma protein binding and limited tissue penetration. Elimination is through renal and biliary excretion into feces.Diagram of flavonoid absorption, metabolism and elimination in the human body. Comprehensive schematic of the pharmacokinetic barriers and metabolic pathways responsible for low orally routed dietary flavonoids bioavailability throughout the human GIT and systemic condition. Intestinal Permeability and Efflux Transporters The cross intestinal epithelium phenomenon is a complex, multi-faceted process to deliver the compounds from GIT wherein the lipophilic aglycones are absorbed through passive transcellular diffusion, and their transport is counteracted by the interactions with the efflux transporters on the apical membrane of the enterocytes.84 Flavonoids, being known substrates and modulators of several ATP-binding cassette (ABC) transporters, most notably P-glycoprotein (P-gp/ABCB1/MDR1), Multidrug Resistance-Associated Protein 2 (MRP2/ABCC2), and Breast Cancer Resistance Protein (BCRP/ABCG2),85,86 gets involved through these efflux pumps and get actively transported the absorbed flavonoids and their Phase II metabolites back into the intestinal lumen, thus significantly reducing their net absorption and intracellular accumulation.87 The interplay between the passive uptake and active efflux creates a substantial barrier to the systemic entry of the orally taken flavonoids, effectively functioning as a “gatekeeper” mechanism that limits the oral route bioavailability of these compounds well before the reach to the site of biological action.88 Extensive First-Pass Metabolism Perhaps the most significant pharmacokinetic hurdle for flavonoids is their extensive first-pass metabolism in both the intestinal wall and the liver.89 Upon ingestion and absorption, the flavonoids are rapidly recognized as xenobiotic materials by the body’s detoxification systems and the flavonoid substrate now undergoes intensive biotransformation before entering the systemic circulation.90 The metabolic Phase II conjugation reactions dominate the flavonoid metabolism. In the enterocytes and hepatocytes, the flavonoids undergo rapid and extensive glucuronidation (mediated by UDP-glucuronosyltransferases, UGTs), sulfation (mediated by sulfotransferases, SULTs), and methylation (mediated by catechol-O-methyltransferases, COMTs).91 Consequently, the parent aglycone form is rarely found in the systemic circulation at detectable concentrations; instead, the administered flavonoids circulate primarily as structurally altered, highly water-soluble conjugated metabolites.92 These conjugates produced as a consequence of metabolic modification as exhibit significantly reduced biological activity as compared to the parent compounds, as the modification of the key hydroxyl groups often diminishes their ability to interact with target proteins and enzymes, although some notable exceptions have been reported.93 Figure 4 presents the four primary therapeutic challenges of administered flavonoids: limited intestinal absorption and membrane efflux (Poor Bioavailability), rapid hepatic and systemic Phase I/II biotransformation (Rapid Metabolism), hydrophobic degradation under environmental and physiological stressors (Poor Solubility and Stability), and systemic dilution due to a lack of organ-specific delivery (Non-Specific Targeting). Figure 4Pharmacokinetic and physicochemical barriers limiting the clinical and pharmacological efficacy of bioactive native flavonoids.The diagram ′Flavonoids Promise in Pharmacology′ highlights challenges in flavonoid pharmacology. Key issues include ′Low oral bioavailability′ due to poor solubility, low intestinal permeability, extensive first-pass metabolism and poor absorption. ′Poor water solubility′ affects dissolution in gastrointestinal fluids, leading to low absorption and formulation challenges. ′Chemical instability′ arises from pH sensitivity, structural degradation and short bloodstream lifespan. ′Rapid metabolism′ results in low active compound levels due to extensive phase II metabolism. ′Limited clinical evidence′ is noted, with most studies being preclinical or in vitro, few clinical trials and insufficient therapeutic data. ′Challenges in formulations and delivery′ emphasize the inefficiency of conventional formulations and the need for advanced systems like nano-formulations and liposomes. Visuals include icons for light, heat, pH, oxygen, liver metabolism and advanced delivery systems.Flavonoid issues: bioavailability, solubility, metabolism, instability, evidence, delivery. Pharmacokinetic and physicochemical barriers limiting the clinical and pharmacological efficacy of bioactive native flavonoids. Rapid Elimination and Short Biological Half-Life The extensive Phase II metabolism not only alters the bioactivity of flavonoids, but also facilitates their rapid elimination from the body.94 The highly polar glucuronide and sulfate conjugates are efficiently excreted through the kidneys into the urine or through hepatobiliary secretion into the bile and subsequently to the feces.95 Additionally, enterohepatic recycling, while prolonging the presence of some flavonoid metabolites, ultimately contributes to their fecal elimination. This rapid clearance results in a very short biological half-life for majority of flavonoids, typically ranging from 1 to 3 hours for monomeric flavonoid compounds.96 The short half-life necessitates frequent dosing to maintain steady-state therapeutic concentrations, which is often impractical and reduces patient compliance in clinical settings.97 This pharmacokinetic limitation severely constrains the design of effective dosing regimens for flavonoid-based therapeutics. Complex Biological Interactions High Plasma Protein Binding Affinity The flavonoids, once in the systemic circulation, exhibit high affinity for binding to plasma proteins, predominantly human serum albumin (HSA).98 Studies using fluorescence spectroscopy and molecular docking have demonstrated that flavonoids bind to HSA at Sudlow’s Site I and Site II with moderate to high binding constants.99 While protein binding facilitates the transport of these poorly water-soluble compounds in the aqueous blood environment and protects them from rapid degradation, it also significantly limits their pharmacological efficacy. Only the unbound (free) fraction of a compound diffuses across the cell membranes to interact with intracellular target receptors, enzymes, and signaling molecules. The extensive protein binding of flavonoids therefore restricts their tissue distribution, cellular uptake, and ultimately their in vivo biological effects.100 Figure 5 illustrates the plasma protein-binding affinity and pharmacological applications of flavonoids, including molecular interactions with human serum albumin (HSA), and α1-acid glycoprotein the binding characteristics, pharmacokinetic implications, and therapeutic activities, such as antioxidant, anti-inflammatory, cardioprotective, antidiabetic, anticancer, neuroprotective, and antimicrobial effects. Figure 5Plasma protein binding properties of flavonoids and their multifaceted pharmacological activities.The infographic highlights flavonoids′ strong plasma protein binding due to their hydroxyl groups and aromatic structures, interacting with human serum albumin (HSA) through hydrogen bonding, hydrophobic interactions, Van der Waals forces and electrostatic interactions. High binding results in a small active fraction, limited tissue distribution, lower clearance and prolonged half-life. Pharmacological benefits include antioxidant (Quercetin, Kaempferol, Luteolin), anti-inflammatory (Apigenin, Chrysin, Luteolin), anticancer (Quercetin, Genistein, Wogonin), cardioprotective (Hesperidin, Naringenin, Quercetin), antimicrobial (Baicalein, Catechin, Myricetin) and neuroprotective activities (Luteolin, Fisetin, Hesperidin).Infographic on flavonoids′ plasma protein binding and pharmacological uses. Plasma protein binding properties of flavonoids and their multifaceted pharmacological activities. Gut Microbiota and Inter-Individual Variability A substantial portion of glycone ingested flavonoids, particularly complex glycoside structures, oligomeric proanthocyanidins, and polymeric tannins, escapes the absorption in the small intestine part of the GIT, and reaches the colon intact.101 These compounds here undergo extensive catabolism by the diverse resident gut microbiota. The colonic microflora possesses rich inventory of enzymes capable of cleaving glycosidic bonds, reducing double bonds, and opening the heterocyclic C-ring, thereupon degrading the flavonoids into smaller phenolic acids and aromatic compounds (eg, hydroxy phenyl acetic acids, hydroxy phenyl propionic acids), that are then absorbed from the colon.102 Notably, some of these microbial-derived flavonoid-based metabolites retain and at times, based on their structures enhance the original and/or newer biological activities, such as antioxidant, anti-inflammatory, and cardioprotective effects.103 Therefore, the pharmacological impacts of flavonoids intake are shaped not only by the parent compound but also by their bioactive microbial metabolites, highlighting the need for a more integrated view of flavonoids efficiency. Critically, the composition, diversity, and metabolic capacity of the gut microbiota vary significantly among individual persons due to differences in genetics, diet, age, health status, and antibiotic usage.104 This inter-individual variability in microbial metabolism leads to profound differences in the structural types and quantities of flavonoid metabolites produced, resulting in their highly variable pharmacokinetic profiles and biological responses among different people consuming the same flavonoid at similar doses.105 This unpredictability poses a major challenge for standardizing flavonoids-based therapies and designing clinical trials with reproducible outcomes. Safety, Toxicity, and Drug Interactions Potential for Toxicity at Supraphysiological Doses The dietary consumption of flavonoids rich food stuff is generally considered safe and well-tolerated; nonetheless, the pharmacological use of high-dose flavonoid supplements and the concentrated extracts raises legitimate safety concerns.106 At elevated concentrations, the flavonoids can illogically lose their antioxidant properties, and act as pro-oxidants to generate reactive oxygen species (ROS) through auto-oxidation and redox cycling to cause oxidative DNA damage and cellular injury. Furthermore, the high doses of certain flavonoids have been associated with hepatotoxicity (eg, high-dose green tea catechins), nephrotoxicity, thyroid hormone disruption, and potential mutagenic and genotoxic effects in specific experimental models.24 The biphasic (hormetic) dose–response relationship of flavonoids emphasizes the importance of establishing safe dose ranges for their pharmacological applications. Drug–Drug Interactions Through Cytochrome P450 Modulations A perilous clinical challenge for flavonoids is to cause significant pharmacokinetic drug–drug interactions (DDIs) since, the flavonoids are potent modulators of the Cytochrome P450 (CYP) enzyme superfamily, particularly CYP3A4, which is the most abundant CYP isoform in the liver and intestine and is responsible for metabolizing approximately 50% of clinically prescribed drugs.107 Many flavonoids act as competitive, non-competitive, or mechanism-based inhibitors of CYP3A4 and other clinically relevant CYP isoforms (eg, CYP2C9, CYP1A2, CYP2D6). Concurrent administration of high-dose flavonoids with certain other drugs metabolized by these enzymes may lead to decreased drug clearance, elevated plasma drug concentration, prolonged drug exposure, and an increased risk of severe levels of adverse drug reactions and ensuing toxicity. The well-documented grapefruit juice–drug interaction, mediated in part by the flavonoids naringenin, exemplified this clinically significant challenge. Traditional Challenges The pharmacological utilization of flavonoids is severely hampered by the complex interplay of physicochemical, pharmacokinetic, and biological challenges (Table 2). The poor aqueous solubility, chemical instability under physiological conditions, low intestinal permeability compounded by active efflux transport, extensive first-pass metabolism via Phase II conjugation enzymes, and rapid systemic elimination collectively result in poor oral bioavailability and limited systemic exposure. The high plasma protein binding, highly variable gut microbiota-mediated metabolism contributing to inter-individual pharmacokinetics variability, and the potential for pro-oxidant toxicity, and clinically significant drug–drug interactions at therapeutic doses have complicated their clinical translation. Overcoming these long-established inherent flavonoids-based drugs and therapeutic modules bioaction efficiency challenges requires innovative and multidisciplinary approaches in safety, solubility, delivery, and precise and only adequate dosing led to nanotechnology-based delivery systems, including liposomal and cyclodextrin complexes for prompt, and safe delivery. The structural modifications and prodrug design strategies to enhance solubility and metabolic stability, the co-administration with absorption enhancers, use of efflux pump inhibitors, and the development of precisely targeted delivery platforms through various ligands attachment has been developed. Also, a deeper understanding of the role of gut microbiota in flavonoid metabolism and the application of precision medicine approach may help address the erratic metabolism of the inter-individual variability of the microbiome and their actions. Addressing these impediments through systematic investigation is essential to bridge the gap among the various promising in vitro potentials of flavonoids and their successful relevance as clinical therapeutics. Table 2Traditional Challenges in the Pharmacological Applications of FlavonoidsChallenges CategorySpecific ChallengeKey ConsequencesReferPhysicochemicalPoor aqueous solubilityLow dissolution rate, limited absorption[27,72,74]PhysicochemicalChemical instability (pH, temperature, oxidation)Degradation in GIT, compound reduced[76,78,79]PharmacokineticsLow oral bioavailability (<5%)Insufficient systemic concentration[81–83]PharmacokineticsEfflux transporter interactions (P-gp, MRP2, BCRP)Active secretion back to intestinal lumen[85–87]PharmacokineticsExtensive first-pass metabolism (UGTs, SULTs, COMTs)Conversion to less active conjugates[89–91]PharmacokineticsRapid elimination and short half-life (1–3 h)Need for frequent dosing, poor patient compliance[94,96,97]BiologicalHigh plasma protein binding (HSA)Reduced free drug fraction and tissue distribution[98–100]BiologicalGut microbiota variabilityInter-individual differences in metabolism/response[101,102,105,108]SafetyPro-oxidant toxicity at high dosesOxidative damage, organ toxicity[24,106]SafetyCYP450 enzyme inhibition (drug interactions)Altered pharmacokinetics of co-administered drug[107] Table 2Traditional Challenges in the Pharmacological Applications of FlavonoidsChallenges CategorySpecific ChallengeKey ConsequencesReferPhysicochemicalPoor aqueous solubilityLow dissolution rate, limited absorption[27,72,74]PhysicochemicalChemical instability (pH, temperature, oxidation)Degradation in GIT, compound reduced[76,78,79]PharmacokineticsLow oral bioavailability (<5%)Insufficient systemic concentration[81–83]PharmacokineticsEfflux transporter interactions (P-gp, MRP2, BCRP)Active secretion back to intestinal lumen[85–87]PharmacokineticsExtensive first-pass metabolism (UGTs, SULTs, COMTs)Conversion to less active conjugates[89–91]PharmacokineticsRapid elimination and short half-life (1–3 h)Need for frequent dosing, poor patient compliance[94,96,97]BiologicalHigh plasma protein binding (HSA)Reduced free drug fraction and tissue distribution[98–100]BiologicalGut microbiota variabilityInter-individual differences in metabolism/response[101,102,105,108]SafetyPro-oxidant toxicity at high dosesOxidative damage, organ toxicity[24,106]SafetyCYP450 enzyme inhibition (drug interactions)Altered pharmacokinetics of co-administered drug[107] Traditional Challenges in the Pharmacological Applications of Flavonoids Antimicrobial Activity of Nano-Formulated Flavonoids Flavonoids induce their antimicrobial effects through several mechanisms, including reducing the ability of the microbes to synthesize their genetic materials to multiply, including nucleic acids, DNA, and RNA; inhibiting the protein synthesis; altering microbial membrane integrity; interfering with the energy production in the microbial cells; and inhibiting the biofilm formation (Figure 6).109 In this context, both the DNA-synthase and RNA-synthase are affected by the flavonoids.110 Four naturally occurring prenylated flavonoids obtained from Dorstenia species are known to inhibit both RNA and DNA synthesis in S. aureus. These flavonoids also induced depolarization of bacterial cell membrane and reduced their density.111 In addition, the minimal inhibitory concentration (MICs) of flavonoids from different classes, including flavones, flavonols, flavanones, flavanols, and catechins, have been tested and the results indicated that the presence of free hydroxyls in the B-ring (positions 3’, 4’, 5’) and A-ring (3-OH) of the flavonoids structure is necessary for their DNA and RNA synthases inhibitory activity. The study by Morl et al reported this activity for kaempferol, morin, quercetin, robinetin, myricetin, and epigallocatechin, and showed that these compounds inhibited the synthesis of DNA and RNAs in P. vulgaris and S. aureus, respectively.112 Zhou et al tested the flavonoid mixtures, including rutin, kaempferol-3-O-rutinoside, astragalin, and isoquercitrin, from Chimonanthus salicifolius.113 They found that these flavonoids induced bacterial cell death by damaging the DNA and compromised the integrity of the bacterial membranes and the cell walls, leading to loss of intracellular components. Transmission electron microscopy (TEM) images, quantitative RT-PCR, and transcriptome analysis indicated that these flavonoids affect microbial DNA, cell walls, cell membranes, and microbial energy metabolism.113 In this context, it is also important to note that the encapsulation of flavonoids in NPs/nanocapsules can significantly alter their pharmacological behavior compared to the free flavonoids.114,115 These nanoformulations often enhance cellular uptake through endocytosis, followed by intracellular trafficking through endosomal and lysosomal pathways.116 After endosomal escapes, NPs enable controlled intracellular release of flavonoids, prospectively resulting in different concentrations at specific subcellular locations. These processes may modify the dominant molecular pathways and the extent of pharmacological activity, therefore leading to improved bioavailability, sustained therapeutic effects, and sometimes altered mechanisms of action.117 Therefore, while Figure 6 summarizes the general antimicrobial mechanisms of the free flavonoids, the mechanisms following nanoencapsulation has been observed to be distinct, and this deserves specific attention in the context of targeted delivery and enhanced pharmacological efficiency. It has been established that the nanoencapsulation of flavonoids has provided improved solubility, stability, safety, of the flavonoids formulation for better cellular uptake, and targeted delivery, thus addressing the flavonoid compounds’ pharmacological limitations.118 Nanoforms of flavonoids are also expected to improve antimicrobial activity by increasing their uptake by microbial cells, thereby overcoming the microbial resistance mechanisms, and improving the overall antibacterial action, also through enhancing the antibiofilm properties.119,120 In this context, Das et al have shown that gold metal-conjugated quercetin (AuNPs-conjugated quercetin) has induced better susceptibility results to E. coli compared to flavonoid quercetin (AuNPs-conjugated quercetin MIC value of 7.6 μg/mL, while quercetin MIC value is at 24.7 μg/mL), and that the AuNPs-conjugated quercetin affected the permeability and integrity of the microbial membrane121 (Table 3). Anwar et al provided another example that validated the flavonoids’ enhanced activity through their incorporation in nanoformulations.122 The study compared the antimicrobial effects of naringin and AuNP-loaded naringin stabilized by gum acacia against A. castellanii and N. fowleri. The AuNP-loaded naringin significantly reduced the viability of microbial cells (P < 0.001) as compared to the pure flavonoid, naringin.122 Similar finding was reported by Jasim et al, indicating that AuNPs conjugated with chrysin induced better antimicrobial activity as compared to the pure chrysin and the unconjugated AuNPs against both the S. aureus and E. coli strains.114 These findings from all the previous studies indicated that the use of chemical methods of AuNPs synthesis was reduced, and with incorporation of flavonoids usually enhanced the antimicrobial activity as against the non AuNPs-loaded flavonoids.123 Moreover, several studies have also recorded substantially better antimicrobial activity for the flavonoid-loaded different NPs, eg, SLNPs, chitosan NPs, and micellar formulation as compared to the free flavonoids.124–126 Other nanoforms prepared as nano-matrix combinations of antimicrobial flavonoids have been also reported. The most recent study of Ramezani et al has investigated the antimicrobial effect of two of the antimicrobial flavonoids, rutin and luteolin, which were encapsulated in chitosan NPs.127 The findings of Ramezani et al indicated substantially higher activity of the chitosan-encapsulated flavonoids against the multidrug-resistant (MDR) P. aeruginosa in comparison to the mixture of unformulated flavonoids (rutin and luteolin separately). The chitosan-encapsulated flavonoid compounds induced MIC values against the MDR P. aeruginosa at 0.78 mg/mL and induced inhibition of the biofilms, which was high (70%) as compared to the MIC value of 3.125 mg/mL and biofilm inhibition at 50% calculated for the free flavonoid mixture.127 Figure 6Antimicrobial mechanisms of flavonoids. The figure adapted based on Mohammed et al 2026.32A diagram illustrating the antimicrobial mechanisms of flavonoids. At the center is a chemical structure labeled A, B, C. Connected to this are several mechanisms: affecting the microbial efflux pump, disrupting the bacterial plasma membrane, inhibiting bacterial adhesion, motility, quorum sensing and biofilm formation, ATP synthase inhibition, DNA replication, inhibition of topoisomerases, DNA gyrase and the replication of DNA, inhibition of dihydrofolate reductase and inhibition of bacterial-type II fatty acid synthase. Each mechanism is depicted with an associated image and label, showing how flavonoids impact various microbial processes.Diagram of flavonoid antimicrobial mechanisms affecting microbial functions. Table 3Antimicrobial Activity of Nanoforms-Flavonoids and Their Mechanisms of ActionFlavonoidsNanoparticle TypesMicrobesEffects LevelMode of ActionReferQuercetinAuNPs-conjugated quercetinE. coliMIC 7.6 μg/mLAffect bacterial membrane.[121]QuercetinP. aeruginosaMIC 30 μg/mL[128]QuercetinK. pneumoniaMIC 60 μg/mL[128]QuercetinP. vulgarisMIC 30 μg/mL[128]QuercetinPoly (vinyl alcohol) [PVA]S. mutansMBIC 128 μg/mLAntibiofilm and production of ROS[129]NaringinAuNPs-loaded naringin and stabilized by gum acaciaMRSA E. coli50 µg/mL and 0.5 µg/mL MRSA and E. coli bactericidal activityInducing disintegration and pores in the bacterial cell membrane[122]NaringeninSolid Lipid NPs (SLNPs)MRSAMIC 0.25 mg/mLInhibition of the metabolic activity and biofilm formation[126]ChrysinAuNPsE. coliMIC 60 μg/mLInhibition of DNA gyrase[128]ChrysinAuNPsS. aureusDose dependent inhibition[128]ChrysinAgNPsP. aeruginosaMIC 50–3.13 µg/mLAntibiofilm[130]ChrysinChrysin-loaded chitosanS. aureusBiofilm development inhibition[131]ChrysinCarrier-free binary nanoparticles with berberineMRSACell death. Inhibits biofilm formation[132]ChrysinCarrier-free binary nanoparticles with berberineCandida albicansAffected M phase progression. Affect cytokinesis. Inhibited hyphal growth. Inhibits biofilm formation[132]ChrysinChrysin incorporated in polycaprolactone (PCL)/gelatin scaffoldsA. baumannii, P. aeruginosa, S. aureus, and E. faecalisInhibition zones ranged from 7.5 to 12 mm[133]KaempferolAuNPsE. coliMIC 60 μg/mLInhibition of DNA gyrase[128]KaempferolAuNPsP. vulgarisMIC 30 μg/mL[128]KaempferolAgNPsE. coliMIC 0.3125 mg/mLAffected bacterial membrane.[134,135]KaempferolAgNPsS. mutansMIC 0.3125 mg/mL[134]KaempferolLecithin/chitosan NPsFusarium oxysporium67% inhibition of F. oxysporium over a period of 60 days.[124]Rutin and luteolinChitosan NPsMDR P. aeruginosaMIC 0.78 mg/mLAntibiofilm formation. Downregulating the biofilm matrix associated gene pelA.[127]LuteolinLuteolin-loaded Methoxy poly(ethylene glycol)-poly(lactide) micellesK. pneumoniaeReducing the adhesion to lung epithelial cells[125]MyricetinZinc oxide NPsC. perfringens isolatesMIC 0.125 to 2 µg/mL and inhibits α-hemolysin toxin production[136]FisetinCombination of polymyxin E with fisetin in nanoemulsionMCR-1-positive S. typhimuriumFisetin enhances the polymyxin E activityInhibition of phospho-ethanolamine transfer of the MCR-1 protein[137]ApigeninChitosan Coated polymerS. aureus, B. subtilis, E. coli, and P. aeruginosaIZD 24–28 mmHigh permeability and solubility compared to free apigenin[138]ApigeninNanoemulsion-based gel containing apigeninP. aeruginosa, E. coli24.86–26.65 mm at 500 µg/mL[139]Berry extract AnthocyaninsFe3O4 nanocompositesS. aureus-902 and E. coliStronge activity against both microbes[140]Black carrot AnthocyaninChitosan/PVA nanocompositeS. aureus, E. coli, and P. aeruginosa44.38–75.20% growth inhibition[141] Antimicrobial mechanisms of flavonoids. The figure adapted based on Mohammed et al 2026.32 Table 3Antimicrobial Activity of Nanoforms-Flavonoids and Their Mechanisms of ActionFlavonoidsNanoparticle TypesMicrobesEffects LevelMode of ActionReferQuercetinAuNPs-conjugated quercetinE. coliMIC 7.6 μg/mLAffect bacterial membrane.[121]QuercetinP. aeruginosaMIC 30 μg/mL[128]QuercetinK. pneumoniaMIC 60 μg/mL[128]QuercetinP. vulgarisMIC 30 μg/mL[128]QuercetinPoly (vinyl alcohol) [PVA]S. mutansMBIC 128 μg/mLAntibiofilm and production of ROS[129]NaringinAuNPs-loaded naringin and stabilized by gum acaciaMRSA E. coli50 µg/mL and 0.5 µg/mL MRSA and E. coli bactericidal activityInducing disintegration and pores in the bacterial cell membrane[122]NaringeninSolid Lipid NPs (SLNPs)MRSAMIC 0.25 mg/mLInhibition of the metabolic activity and biofilm formation[126]ChrysinAuNPsE. coliMIC 60 μg/mLInhibition of DNA gyrase[128]ChrysinAuNPsS. aureusDose dependent inhibition[128]ChrysinAgNPsP. aeruginosaMIC 50–3.13 µg/mLAntibiofilm[130]ChrysinChrysin-loaded chitosanS. aureusBiofilm development inhibition[131]ChrysinCarrier-free binary nanoparticles with berberineMRSACell death. Inhibits biofilm formation[132]ChrysinCarrier-free binary nanoparticles with berberineCandida albicansAffected M phase progression. Affect cytokinesis. Inhibited hyphal growth. Inhibits biofilm formation[132]ChrysinChrysin incorporated in polycaprolactone (PCL)/gelatin scaffoldsA. baumannii, P. aeruginosa, S. aureus, and E. faecalisInhibition zones ranged from 7.5 to 12 mm[133]KaempferolAuNPsE. coliMIC 60 μg/mLInhibition of DNA gyrase[128]KaempferolAuNPsP. vulgarisMIC 30 μg/mL[128]KaempferolAgNPsE. coliMIC 0.3125 mg/mLAffected bacterial membrane.[134,135]KaempferolAgNPsS. mutansMIC 0.3125 mg/mL[134]KaempferolLecithin/chitosan NPsFusarium oxysporium67% inhibition of F. oxysporium over a period of 60 days.[124]Rutin and luteolinChitosan NPsMDR P. aeruginosaMIC 0.78 mg/mLAntibiofilm formation. Downregulating the biofilm matrix associated gene pelA.[127]LuteolinLuteolin-loaded Methoxy poly(ethylene glycol)-poly(lactide) micellesK. pneumoniaeReducing the adhesion to lung epithelial cells[125]MyricetinZinc oxide NPsC. perfringens isolatesMIC 0.125 to 2 µg/mL and inhibits α-hemolysin toxin production[136]FisetinCombination of polymyxin E with fisetin in nanoemulsionMCR-1-positive S. typhimuriumFisetin enhances the polymyxin E activityInhibition of phospho-ethanolamine transfer of the MCR-1 protein[137]ApigeninChitosan Coated polymerS. aureus, B. subtilis, E. coli, and P. aeruginosaIZD 24–28 mmHigh permeability and solubility compared to free apigenin[138]ApigeninNanoemulsion-based gel containing apigeninP. aeruginosa, E. coli24.86–26.65 mm at 500 µg/mL[139]Berry extract AnthocyaninsFe3O4 nanocompositesS. aureus-902 and E. coliStronge activity against both microbes[140]Black carrot AnthocyaninChitosan/PVA nanocompositeS. aureus, E. coli, and P. aeruginosa44.38–75.20% growth inhibition[141] Antimicrobial Activity of Nanoforms-Flavonoids and Their Mechanisms of Action The mode of action of flavonoid-based nanoforms as antimicrobial materials indicated that these formulations inhibit microbial growth in various ways, including inducing ROS overproduction, thereby affecting microbial cell wall and membranes, and inhibiting protein and DNA, and RNA synthases (Table 3).121,128,129 Furthermore, the flavonoid encapsulated NPs have induced inhibition of biofilm formation through downregulation of the biofilm matrix genes, such as pela, and affected the microbial cell division (Table 3).127,131,132 Table 3 represents several flavonoids nanoforms and their antimicrobial activities. Antiviral Activity of Nano-Formulated Flavonoids Flavonoids as antiviral agents have posted significant value, especially in the context of recent past pandemics. Hence, there is still a pressing need for antiviral drug discovery owing to the perilous and potentially lethal ramifications of viral infection as experienced worldwide.142 Natural products, including flavonoids are a potent lead for antiviral compounds.143 These products have multi-functional effects such as antioxidants, anti-inflammatory, and immunomodulating effects that participate in enhancing the overall health condition of the host.32 The antiviral mechanisms of flavonoids differ according to the incoming viral structure. For enveloped viruses, such as SARS-CoV-2, influenza, and HSV, flavonoids can interfere with the viral life cycle by inhibiting the viral proteases (eg, 3CLpro in coronaviruses), preventing spike protein’s binding to the host cell membrane receptors (such as ACE2), and disrupting the viral envelope fusion with the host membranes.32 Certain flavonoids, like quercetin and luteolin, have demonstrated selective inhibitions of 3CLpro, while other modulates the interaction between the spike proteins and the host receptors.144 In contrast, for unenveloped viruses, the mechanisms involves inhibiting the capsid assembly, or interfering with the viral genome replication.145 These pathways-specific actions underline the versatility and potential for targeted flavonoids therapies against a spectrum of viruses. Nonetheless, the limited bioavailability and aqueous solubility of several flavonoids affect their therapeutic applications in this segment, ie, anti-virals.29 To overcome these difficulties, integrating the flavonoids into nanocarriers and nanoplatforms have been used to enhance the solubility and provide protection against metabolic degradation to improve delivery (Figure 7). Figure 7Diagrammatic representation of functions of nano-formulations in augmenting the antiviral efficacy of flavonoids. The arrows express the configuration of flavonoids in specific nanoforms that served to improve the solubility, stability, and safeguard from degradation as well as to facilitate the regulated release of flavonoids.The diagram illustrates the transition from free flavonoids to flavonoid nanoparticles (NPs) to enhance antiviral activity. Free flavonoids face challenges such as poor aqueous solubility, low stability (pH, metabolism), rapid degradation (GIT/liver) and low cellular uptake, leading to limited antiviral activity. Flavonoid NPs include polymeric NPs (PLGA), nanoemulsions, bilosomes/liposomes and metal NPs. These NPs improve solubility, stability, provide protection from degradation and allow controlled release, resulting in enhanced antiviral activity.Diagram of flavonoid nanoformulations enhancing antiviral activity. Diagrammatic representation of functions of nano-formulations in augmenting the antiviral efficacy of flavonoids. The arrows express the configuration of flavonoids in specific nanoforms that served to improve the solubility, stability, and safeguard from degradation as well as to facilitate the regulated release of flavonoids. The incorporation of flavonoids into nano-based delivery systems, such as polymeric NPs (eg, PLGA NPs), nanoemulsions, bilosomes/liposomes, and metal NPs, have improved their physicochemical and biological performance. These nanocarriers have enhanced flavonoid solubility and stability, protected them from premature degradation, and have enabled controlled and sustained release. As a result, nanoformulated flavonoids exhibit improved bioavailability, better cellular delivery, and enhanced antiviral efficacy against the viral infection as compared with the corresponding free, pure flavonoid compounds. The structure–activity relationship and mechanism of action of flavonoids in trapping/inhibiting the viruses have been reported.32 Several nano-based formulations have been shown to exhibit greater antiviral activity than the pure, non-formulated flavonoids. For instance, hesperidin has served as a reducing agent in the synthesis of zinc oxide NPs. Following the evaluation of the pure compound and its NPs-mediated form tested against hepatitis has shown that the flavonoid-mediated NPs had superior anti-viral activity as compared to the hesperidin.146 Another report further confirmed this notion through testing Maesa indica extract containing phenolic acids, naringenin, quercetin, kaempferol, and luteolin in comparison with its ZnONPs-counterword nanoform formulation for coronavirus (229E) therapy. These results indicated that the prepared ZnONPs demonstrated IC50 and selectivity index (SI) values of 7.15 µg/mL and 40.92, respectively, as compared to 9.97 µg/mL and 23.66 for Maesa indica unformulated extract.147 Moreover, the ZnONPs prepared from the Plumbago indica extract, which is rich in polyphenolic compounds including rutin, demonstrated significant anti-HSV-1 activity (IC50 23.17±2.29), and exhibited higher selectivity as compared to the activity of the non-nano formulated (extract as such) plant extract against the virus (IC50 54.6±1.53).148 Furthermore, under the in vitro study of Hamulati et al, it was revealed that the nano-encapsulation of Artemisia rupestris L. flavonoids within a PLGA-based nanoformulation system markedly improved the anti-hepatitis B virus (HBV) efficacy. In comparison to the crude flavonoid extract, PLGA-based nano-encapsulations more efficiently inhibited the HBV replication-dependent markers, such as, HBsAg, HBeAg, and HBV DNA secretion in HepG2.2.15 cells.149 The findings reported by Santos et al underscored the poor bioavailability and stability of the non-formulated C-glycosyl flavonoids from Cecropia glaziovii, which limited their antiviral efficacy. In contrast, when encapsulated into PLGA NPs, the flavonoid-enriched fraction of the plant exhibited better stability and a controlled, sustained release profile of the compound.150 While the non-formulated C-glycosyl flavonoids demonstrated stronger and quick inhibition of HSV-1 replication within 48 hours, the nano-formulated version showed stronger and prolonged antiviral activity consistent with its gradual release kinetics.150 The results emphasized the nano-encapsulation advantage and offered an alternate and viable strategy to overcome the solubility and permeability issues of the C-glycosyl-based flavonoids, and substantially enhanced their long-term therapeutic performance.150 Mahmoud et al investigated the antiviral potential of polyphenols-rich Cuphea ignea extract against SARS-CoV-2.151 Their study identified key bioactive compounds, including rutin and myricetin-3-O-rhamnoside, which demonstrated strong binding affinity against the viral main protease through molecular docking. To enhance the solubility, stability and bioavailability, a self-nanoemulsifying drug delivery system (SNEDDS) was developed for use of the SNEDDS under acidic conditions. The optimized formulation exhibited complete in vitro viral inhibition at low concentrations (5.87 μg/mL), thereupon suggesting a synergistic antiviral effects of the extract constituents, which highlighted the nanoformulation approach outreach as potential therapeutic module against COVID-19.151 Overall, the accumulated evidence strongly supported the nano-based delivery systems significant role in enhancing the antiviral potentials of flavonoids through overcoming the flavonoids inherent physicochemical and biopharmaceutical limitations. These advantages, coupled with the potential for synergistic interactions in complex formulations, positioned nanoformulated flavonoids as a promising and versatile module for developing more effective antiviral therapeutics from the existing compounds. Flavonoids Nanotechnical Formulations for Pandemic Challenges Advancements in Nanotechnology for Flavonoid Delivery The significant pharmacological activities of flavonoids, especially in the context of pandemic healthcare needs, are often limited by their inherent physicochemical challenges, such as poor aqueous solubility, lipophilicity, and low gastrointestinal absorption.29,32 These barriers hinder their effective delivery and therapeutic potential. As a result, nanotechnology-based formulation strategies have emerged to address these issues, offering improvements in formulation, drug absorption, stability, bioavailability, targeted delivery, controlled release, optimal dosing, metabolism, and, when applicable, reduced toxicity.152 The nanotechnology based significant formulation advancements in the field have enabled the use of the flavonoids as part of the therapy under pandemic and non-pandemic situations.153,154 Nanocarriers, such as liposomes, polymeric NPs, and SLNPs have worked as a significant tool for the delivery of flavonoids. Liposome, consisting of phospholipid bilayers and ingrained with the bioactive compound, safeguards the hydrophobic compounds from degradation in the GIT. Researchers have observed that encapsulation of natural compounds such as quercetin, a flavonoid, in liposomal formulations enhances its bioavailability compared with the non-encapsulated free form.155 The SLNPs and other nanostructured lipid carriers (NLCs) were also prepared from the biodegradable and biocompatible lipids as encapsulate materials for flavonoids, including the resveratrol, a highly lipophilic product. The formulation provided enhanced stability against biological variables of the degradation and metabolism.156 Towards the targeted delivery, the binding of on-site directing ligands, such as antibodies, folic acid, peptides and other on-site binding compatible molecular motifs attached to the carrier nanosystems for facilitating the payload delivery have been employed. The delivery to specific cells through the overexpressing specific receptors motifs have been also used.157 Folic acid-linked NPs delivered quercetin to breast cancer cells, thereby resulting in significant reduction in development of tumor as observed in animal experiments.158 Another aspect of delivery, the passive targeting relied on the enhanced permeability and retention (EPR) effects of the under-study molecules. The approach facilitated the targeted delivery under diverse tissue conditions obtained by poor vascularity.159 The approach also facilitated the functions of the target receptors, stimulated by pH, or enzymes, also for an unknown target location. The pH-sensitive chitosan formulatory preparation released high concentrations of genistein under acidic medium in the tumor microenvironment, and reduced the unwanted effects.160 Other than for cancer therapeutics, the flavonoid NPs have been used in treating neurological and cardiovascular disorders. Hesperidin-based nanoemulsion enhanced the anti-hypertensive activity, while the quercetin encapsulating NPs were facilitated through the bloodstream, and revealed certain levels of neurological outcomes in Alzheimer’s disease models.161 However, the need and hurdles to scale up various formats of nanoformulations preparative process for large‑scale production for clinical and commercial use remain elusive, barring the liposomal preparation methodologies. Nanoscale Flavonoid Formulations’ Advantages in Therapeutics Flavonoids nano-scale formulation have effectively overcome several drawbacks including solubility, rapid metabolic degradation, and failure to inhibit systemic absorption (see Figure 8).162 Nanotechnology has opened new avenues for drugs better carrierability, safety, stability, intact packaging, site-directedness and adverse effects control through maneuvered encasing and attachment leading to improved bioavailability, precisely-targeted delivery, selective accumulation in diseased tissues, and reduced risks.163,164 Figure 8Drug delivery technologies involving drug encapsulation.164Diagram of various drug delivery systems including lipid, polymer and micelle types. Drug delivery technologies involving drug encapsulation.164 Studies have shown that apigenin-loaded NPs bound to folic acid preferentially binds to the cancer cells that had overexpressed folic acid receptors, thereby enhancing the antitumor activity while sparing the healthy cells.165 This active targeting reduced the systemic toxicity, a common drawback of conventional chemotherapy. The passive targeting through enhanced permeability and retention (EPR) of NPs allowed for the drug accumulation in the microenvironments of the leaky tumors, thus further improving the delivery and treatment precision.166 Nevertheless, it should also be noted that the conventional enhanced permeability and retention (EPR) effects were first identified in highly vascularized, fast developing tumors in rodents, while in humans for the malignancies its significance was markedly lesser, consistent and variable.167 It was suggested through clinical and translational observations that human tumors, when compared to animals conditions of tumors, had far less vascular permeability, greater interstitial fluid pressure, and a more complex stroma.168 Therefore, the certainty of the passive buildup of NPs is lower in humans than in animal models. Consequently, depending only on the ERP effects may lead to an overestimation of the translational potential of the passive targeting phenomenon, which emphasized the need for incorporating, or providing substitute designs relying on the EPR effects with strategies to integrate tumor microenvironment specifications, and its changing modalities. The strong modifications over the time in tumor may lead to active targeting choices with patient-specific stratification to achieve the goals of molecularly, pharmacologically, and physiologically clean and precise drug delivery to provide the designated, and safe therapeutic outcomes.169 In this context, the controlled release mechanisms enhanced the flavonoids delivery through specified and superiorly developed nanosystems/nanoplatforms with layered development of the nanocarrier achieving chronological, site-specific and various stimuli-responsive advantages of activation that includes the pH, temperature, time, and specific enzymes to ensure drug release at the site. These systems are particularly valuable in chronic conditions that had required prolonged drug exposure, as in neurodegenerative diseases.123 Epigallocatechin gallate (EGCG) nanostructures were investigated for their ability to cross the blood–brain barrier (BBB), that provided neuroprotective effects in Alzheimer’s disease models by mitigating the oxidative stress and amyloid-beta protein accumulations.124 Beyond oncological and neurological interventions, the flavonoid nanosystems have shown promising potential in cardiovascular and dermatological applications. Nanoemulsifications encapsulating the hesperidin enhanced its absorption to aid in the management of hypertension. Meanwhile, the topical delivery of resveratrol through nanostructured lipid carriers promoted photo-protection and provided anti-aging effects through improving the skin penetration, as demonstrated in Figure 9.170,171 Figure 9Concentration versus Time relationship for oral administration of hesperetin (Hes) suspension and hesperetin nanoemulsion (Hes-NE) to rodents.170A line graph showing the concentration of (Hes) and (Hes-NE) over time in rats. Concentration versus Time relationship for oral administration of hesperetin (Hes) suspension and hesperetin nanoemulsion (Hes-NE) to rodents.170 Pandemic Context and Flavonoids Formulation Developmental Actions Viral Infections and Nano-Formulated Flavonoids Viral infections have become a global health concern. The infections have been aggravated by the emergence of drug-resistant viruses, and the scarcity of effective antiviral therapies. Flavonoids, polyphenolic compounds, have exhibited broad-spectrum antiviral activity by inhibiting viral entry, replication, and aggregation. However, the clinical efficacy of these products is limited by their insufficient solubility, rapid metabolism, and inadequate tissue penetration. Nanotechnology has effectively offered solutions for enhancing the delivery and increasing the efficacy of the flavonoid-based antiviral agents, some of which have been used as part of nutraceuticals. Alternative medicine and immune boosters, despite their full clinical trials evaluations. However, these emergency uses of flavonoid products have provided benefits worth mentioning and made way out as part of solution for enabling the targeted tissue delivery and improved solubility, stability, safety and reduced toxicity as observed in later pharmacological studies. The anti-viral nano-delivery techniques have successfully overcome the flavonoid inherent and wide-spread inhibiting limitations of non-encapsulated flavonoid therapeutic modules. This included the liposomal and various filamentary and dendrimer units. Quercetin, a potent antiviral flavonoid, exhibits limited bioavailability in its native form. Encapsulation in liposomal formulations and PLGA nanoparticles can improve its solubility and persistence in the bloodstream by extending its biological half-life, thereby enhancing delivery to target cells. Research has also shown that quercetin inhibits influenza A virus replication by interfering with viral entry and fusion with host cells.172 Patents for quercetin SLNPs are known for their enhanced efficacy in respiratory phenotype cells, which limited the viral load of the SARS-CoV-2 by inhibiting the functions of 3-chymotrypsin protease (3CLpro), the key enzyme required for viral replication.173 Active targeting is known to enhance the effectiveness of antiviral agents. Equipping NPs with site-directed carriers, such as antibodies and peptides facilitated the targeted delivery of the payload to the viral reservoirs, and also the infected cells. Glyceryl sulfate-conjugated NPs are loaded with baicalin. A flavonoid derived from the Scutellaria baicalensis plant, specifically targeted the hepatitis B virus (HBV) spike protein. This improved the intracellular delivery and inhibited viral DNA synthesis. This approach reduced the side effects and lowered the required dose to achieve the desired therapeutic results. Furthermore, nanocarriers-enabled combination therapy has proven to be a vital advantage in combating rapidly evolving viruses.174 The concomitant use of flavonoids with conventional antivirals, such as oseltamivir and remdesivir, has demonstrated synergistic effects. A recent study showed that luteolin and zanamivir encapsulated together in chitosan NPs achieved 90% inhibition of neuraminidase activity in the drug-resistant influenza viruses, as compared to 50% inhibition with the non-encapsulated drugs.175 Despite these advances, certain challenges remained. The long-term safety profile of the nanocarriers and their large-scale production capabilities, as well as regulatory approval procedures, all require careful treading. The diverse interactions of flavonoids with NPs necessitate formulations tailored to specific needs of the particular virus. Nanoformulations-based flavonoid delivery techniques represent a promising avenue for antiviral therapy development, through overcoming the bioavailability barriers and enabling the multifunctional targeted interventions. These developments can further revolutionize the management of viral diseases, including influenza, HIV, and lethal viruses, such as SARS-CoV-2.176 Drug Resistance Control Using Flavonoid Nanotechnology-Based Formulations Drug inactivation by enzymes and genetic alterations are significant factors that can lead to drug resistance, a critical drawback in treatment of bacterial infections, malignancies, and fungal disorders. Therefore, it’s needed to develop new approaches for precise and robust drug delivery module. Nonetheless, the flavonoids offered multi-pronged solutions to disrupting resistance pathways and maintained their antibacterial and anticancer properties. However, their therapeutic values are limited by their rapid elimination and low bioavailability. Nanotechnology-based formulations improved their transport, stability, and on-site targeted activity to effectively combat infections and the drug-resistant cells and their pathways. The methicillin-resistant Staphylococcus aureus (MRSA) was tackled through quercetin-loaded liposomes in conjunction with ciprofloxacin to enhance its effectiveness. The nanostructured formulation enhanced the cellular uptake, inhibited excretory pumps (P-glycoprotein), and disrupted the biofilm formation. The formulation, reduced the required antibiotic’s dose by 70% in mouse models.177 Similarly, flavonoid-loaded PLA nanoparticles can reverse chemotherapeutic resistance in ovarian cancer by downregulating anti-apoptotic proteins such as survivin and Bcl-2 and enhancing sensitivity to paclitaxel, leading to stronger tumor suppression than the free drug.178 Also, the silver-flavonoids NPs have been shown to simultaneously inhibit biofilm formation and microorganism growth. Using naringenin-coated silver NPs, azole resistance was overcome by disrupting the Candida albicans biofilm with improved fluconazole efficacy.179 Additionally, the nano-technique also enabled the development of combination drugs therapeutic modules that directly targeted multiple resistance mechanisms. When epigallocatechin gallate (EGCG) and doxorubicin were combined in hyaluronic acid NPs, the concentration of the accumulated drug in multidrug-resistant breast cancer cells was significantly increased. Preclinical studies had shown that this combination inhibited hypoxia-mediated pathways, thereby resulting in a 90% reduction in tumor growth.180 The biocompatibility and biodegradability of the NPs, scaling-up of the manufacturing are the primary challenges that need to be addressed. Moreover, the surface modifications through various molecular motif of polymeric and non-polymeric origins, frequently used polyethylene glycol (PEG), capping, physiological stimuli-responsive designs, through use of pH and enzymes trigger drug release have the potential to reduce drug toxicity and enhance the site-specific selectivity.181,182 Despite the encouraging in vitro and preclinical studies on some flavonoids, such as quercetin, and catechins, the clinical and epidemiological trials have not been found consistently positive.183 Although several approaches and meta-analyses indicated that supplementation of quercetin leads to moderate decline in blood pressure, while it enhanced specific cardio-metabolic markers. Other randomized investigations utilizing pure quercetin stated that vascular functions and cardiovascular risk status were not been significantly impacted.184 Clinical and preclinical data indicate that quercetin and flavonoid-rich interventions beneficially affect blood lipids, blood pressure, and markers of systemic inflammation in metabolic syndrome and related disorders.185 However, systemic reviews underscored that outcomes across clinical conditions were diverse, whereas certain medical conditions (eg neurodegenerative disorders) showed minor, or no clinical merit. Several studies were restricted by small sample size and formulation of variables. However, clinical evidences on catechins proved discrepancy, since despite observational and interventional investigations connected the green tea catechins to decreased cardiovascular threats in some cohorts, other randomized studies showed failure to prove clear impacts on specific endpoints, or demonstrated advantages that were limited to specific subgroups, or dose levels. Overall, the contrarily mentioned, or context-based outcomes were found to focus on constant gap between the significant mechanistic findings, and the varying in vivo effectiveness, which emphasized the necessity of approaches. The mechanistically guided, properly standardized, ample-sized, and formulation-attentive studies for assessment of flavonoid-based therapies are recommended.186 Notwithstanding the nanotechnical advancements in the flavonoids-based therapeutic modules development, the pharmacological applications of the flavonoids therapy are not consistent and positive in epidemiological evaluations. Several nanoformulations have shown significant improvements in solubility, encapsulation effectiveness and in vitro properties,30 these physiochemical enhancements did not always yielded improvements in oral bioavailability or activity enhancements. Systemic and narrative reviews of nano-delivery systems emphasized the cases where NPs, or nanoemulsion had led to moderate changes in the pharmacokinetic parameters or had failed to yield statistically significant benefits over traditional formulations, when assessed under physiologically significant conditions. In some cases, more systemic exposures after nanoencapsulation could not improve the therapeutic outcome, which suggested that aspects like fast clearance, suboptimal tissue distributions, carrier-immune interactions, and the predominant metabolites’ role had restricted the functional merits.187 Certain other reports showed the limitations linked to scalability, batch-to-batch reproducibility, long-term safety, and the regulatory acceptance, which had the potential to confine the practical utility of the otherwise refined nano-architectures.188,189 These adverse and neutral results also explicitly suggested that the nanotechnology-based advances in the drug delivery and development cannot be considered as a universally efficient remedy for flavonoid therapy, instead it should be regarded as a toolkit that has potential and can be utilized appropriately and assessed critically on a case-by-case basis.190 Under these considerations, a balanced view of both successful and unsuccessful nanoformulation approach is vital, and it may also provide the reasons for examining how particular nanoplatforms can be rationally employed as well as strictly examined to surmount the documented restrictions of flavonoids’ stability, bioavailability, and biological activity. In this context, it is critical to recognize the constraints imposed by the nanoformulations used to deliver the flavonoids. Several nanocarriers are dependent on inorganic cores, surfactants, and a number of synthetic polymers, which are known to produce toxicity on long-term use. These entities have issues of biodistribution and clearance, and the produced off-shoot byproducts and transformed metabolites, together with the additive compounds, and these products’ structural identity being unknown, there remains concerns about their potential build-up in the body, including in the off-target organs and lymphatic systems, with accumulative and the original dose-dependent side effects.191,192 Moreover, unintentional immunological responses, such as complement activation, and rapid opsonization can also be induced by the surface modifications intended for improving the circulation time and targeting. Consequently, alterations in the pharmacokinetics profile, reduction in biological efficacy, and provoked infusion-related reactions also occur.193 From a translational viewpoint, the complex composition of these nanosystems entails for significant manufacturing difficulty that involves accomplishing large-scale, GMP-compliant productions with strict control over particle size, polydispersity, surface charge, and the drug loading, which is technically very challenging, where little variation in the parameters of the process has the potential to result in pronounced batch-to-batch variability.194,195 These concerns have hindered the quality control and regulatory approvals of nanoformulations and have restricted their feasibility for large-scale production and cost-effectiveness for extensive clinical applications. Although the nanotechnical approach for flavonoids’ drug development has provided worthwhile tools to control the key constraints of flavonoids, the nanoformulations’ design must also meticulously balance the solubility and bioavailability parameters, with carrier-related toxicity, immunogenicity, and manufacturability of the nano-formulated end-product.196,197 Nano-Flavonoids Applications Pharmaceutical Rationale Pharmaceutical rationale for incorporating flavonoids into nanocarrier systems lied primarily in the intrinsic physicochemical (poor aqueous solubility, limited gastrointestinal permeability) and biopharmaceutical (low oral bioavailability, and extensive presystemic metabolism) limitations of this class of compounds. Majority of flavonoids exhibit these traits, which restricted their systemic exposure and have reduced the therapeutic efficacy after conventional oral administration. Nanostructured delivery modules have been designed to overcome these barriers through improvement in flavonoids solubility and dissolution, protection of flavonoids from chemical and metabolic degradations, and modulation of pharmacokinetic behavior to prolong circulation and enhance the intended tissues’ exposures.198,199 Additionally, the nanostructured carriers by planned design provide increased cellular uptake, tend to facilitate transport across biological barriers, and also enable passive and active tissue-specific delivery, as the designed platform be, thereby improving the localized drug concentration, while potentially reducing the off-target toxicity. Given for these reasons, the nanostructured, especially NPs and various molecular tags/specific attachment-enabled, modified NPs-based, formulations have not only been a mere alternative for dose-control with various dosage form modalities for delivery, but also been a pharmaceutical strategy aimed at translating the inherent biological activity of the flavonoids into more precise, self-directed, specific, accurate and adequate-dosed with continuous and sustained, and reliable delivery carrier for achieving the better in vivo performance.197,200 Anticancer Action Anticancer drug delivery represents one of the most extensively investigated applications for flavonoid-loaded nanocarrier entities. The flavonoids possess well‑documented anticancers activities, together with the relievable modulations of oxidative stress, apoptosis, inflammation, angiogenesis, metastasis, and cell-cycle regulation. However, the clinical translation of the therapeutic efficacy into oncological practice is amply limited by flavonoids poor solubility, rapid metabolism, and the flavonoid drug’s insufficient accumulation at the tumor site after the administration of the drug in its pure and free form.201,202 Nanocarrier systems including polymeric NPs, SLNPs, and other prepared nanoplatforms, eg, micelles, and the nano-hybrid platforms have been widely used to improve the tumor on-site delivery. These nano-enabled molecular structures enhanced the drug loading and provided protection for the physiologically and chemically labile compounds from premature degradation, unwanted pharmacokinetics, generating toxicity, and haphazard biodistribution. An increase in intratumoral exposure through prolonged encased/entailed drugs’ systemic circulation, tumor outreach was observed. The nanoentities surface-functionalization through chemical, biochemical appendages attachments and cell/tissue microenvironment modulation, provided different targeting strategies for the precise delivery of the drug. Several studies have reported the nanoformulated flavonoids enhanced anti-improve efficiency with reduced systemic toxicity as compared with the free flavonoids tumoral deliveries. The notion substantiated the vast potential of the utility of the nanotechnical approaches for the desired drug deliveries in oncological and other biochemical-physiological conditions of various diseases/disorders. Thus, the flavonoids role as the chemotherapeutic adjuvants and as a standalone bioactive agents for cancer management has been made possible.203,204 Vaccine Development Features The prospects for improved vaccine development from the nano-modulated flavonoids seem to hold promise, which may have a major impetus for enhancing and modulating the immune responses. Flavonoids, that can serve as natural adjuvants for boosting vaccine efficacy owing to their immunomodulatory, antioxidant, and anti-inflammatory properties, forms the good candidate for the same activities. Notwithstanding their limited bioavailability, the nanotechnology-based flavonoids-origin vaccine development can offer solutions to circumvent the formulative and structure-property challenges posed by the pure, free form flavonoids. The process could enable precise delivery and promote synergistic interactions between the immune cells and the antigens. Use of flavonoid-centered NPs as adjuvants may hold promising avenues for further exploration, and towards effective vaccine development. The quercetin encapsulated in polymeric NPs and as liposomal entrapments has meaningfully improved the dendritic cells maturation and antigen presentation. The polymeric NPs exhibited controlled release pattern, particularly the NPs prepared from biodegradable polymer, poly(lactic-co-glycolic acid) (PLGA). The PLGA-coated quercetin NPs demonstrated prolonged payload release for more than 72 hours, thus enhancing the anticancer activity as observed in preclinical animal trials.205 A quercetin-loaded nanoemulsion has also been investigated as an adjuvant for mucosal vaccination because quercetin effectively attenuates oxidative stress in mucosal tissues and enhances antigen uptake by phagocytic and dendritic cells.206 The nano-architecture based delivery carriers have enabled simultaneous administration of flavonoids and the antigens within a single carrier system, thereby increasing their uptake by immune cells. Lipid nanoparticles (LNPs), originally designed for mRNA vaccines against COVID-19, were modified to incorporate flavonoids, such as epigallocatechin gallate (EGCG) together with mRNA antigens, hence representing a significant advancement in vaccinology.207 Studies have shown that nanotechnology-based delivery and site-localization nanosystems have enhanced the antigen expression through mRNA (messenger RNA) transfer to mitigate the hyper-inflammation of the antioxidant character of the epigallocatechin gallate (EGCG). It procedure also enhanced the targeting efficacy of the functionally modified NPs. The mannose-decorated and apigenin-loaded dendrites have also been shown to preferentially bind to the mannose receptors on the antigen-presenting cells, thus increasing the cross-reactivity and cytotoxic T-cell responses.208 There is also growing interest in developing heat-resistant, single-dose vaccines through nanotechnology-based approaches. When flavonoids, such as luteolin, are incorporated into silica NPs, they have protected vaccine antigens from thermal degradation. The process has been advantageous for dissemination the combined dose in resource-crunched situation and also avoided separate double delivery.209 Also, the stimulus-responsive system working in the pH specified situation, the chitosan NPs, have simultaneously released flavonoids and antigens together into specific compartments, and enhanced immune activation while minimizing the systemic damages. There are certain obstacles facing these technologies, that include scalability, extensive safety profiling, quality assessments, and regulatory approvals. Nonetheless, initial trials in preclinical studies have demonstrated the viability of this approach. It has also been proven in another preclinical investigations that lipid nanoparticles (LNPs) which are co-loaded baicalein flavonoid and mRNA vaccines have simultaneously restricted the viral replication and regulated the excessive inflammation.210 The flavonoids and Toll receptor (TLR) agonists, or immune checkpoint inhibitors, to target complex malignancies and pathogens in cancer therapy have also been suggested. However, future research needs to prioritize the hybrid systems that combine flavonoids with the biochemical entities. Nanotechnology, have thus, offered and still presents resources that have the potential to improve the precision, efficacy, and global accessibility of the treatments through better and new vaccines. Thus, the nanotechnology-based flavonoids delivery platforms, and nanoscale prepared vaccines have the potential to enhance pandemic preparedness for future by enabling the rapid production of multilayered, complex and multifunctional vaccines and other nano-engineered medications. Impacts on Health Solutions The flavonoid-based nanopharmaceuticals have offered delivery modules that dispense requisite and adequate doses of the drugs and vaccine materials. Innovation has met the expectations of global health challenges through competitive, safe, sterile, robust, repetitive, and feasible delivery modules and standardized preparative procedures. Studies to confirm and validate the dual-component deliverable formulations with retained antigenic efficacy under biological environments have also been conducted. Nonetheless, the technology is relevant for resource-scarce countries with limited access to medical equipment and extensive medical services and facilities. The nanotechnical procedures have facilitated the development of sustainable, rational and viable, thermally and chemically/biochemically stable, and cost-effective therapeutic modules of various kinds, offered through better scalability, which have the potential to impact disadvantaged communities. In this context, the sustainable resources of flavonoids, which include natural product isolates, expertise, and raw materials for creating nanosystems from scratch, as well as distribution and delivery, are significant factors in adopting this technology.29 Scope for New Nano-Formulated Flavonoid Products, and Regulatory Requirements The environmentally benign, biocompatible, biodegradable, eco-friendly, and sustainable flavonoids and nanoformulatory raw materials have the potential to produce activity-enhanced nanomedicines to effectively impact the communities’ health around the world. The notion of the circular economy can be further supplemented by the repurposing of natural recyclable materials into nano-based drugs. The use of citrus peels, rich in flavonoids, and other natural and biological raw materials, including chitosan, pectin, albumin, antigens, peptides, etc, and differently sourced pure natural flavonoids fill this aspect in new flavonoid-based complex and multi-layered nano-engineered drug development. A number of flavonoid-based nanoformulations with therapeutic efficacy against various diseases,211 especially cancers, have been developed and are under preclinical and very early primary clinical evaluation stages.206,212 The approach of flavonoids and US FDA-approved drugs for combination therapy is gaining traction. Another aspect of new drugs’ development and their launch constitute the regulatory harmonization and feasible and robust technology transfer to low- and middle-income countries (LMICs). Collaborative initiatives emphasizing open-shared research, technology, and capacity-building can provide the much-needed impetus in this regard. When it comes to eliminating constraints on healthcare access and sustainability, the nanotechnology-powered flavonoid drug-based systems have the potential to transform global health. With this approach, the nanotechnological advancements in drug development would be of at least nearly evenly distributed benefit to all and would reach those who are economically disadvantaged. Prospects and Future Outlook Traditional medicine, especially phytomedicines, has been warped because of pharmaceutical, preclinical, and clinical challenges. The nanotechnology-based way out of these constraints has significantly impacted healthcare at personal and community levels. The promise of the nanotechnique still holds essence and has further and farther implications in the future. The importance of these achievements in combating various diseases is being emphasized regularly. Cardiovascular diseases, infectious situations, and diabetes are highly widespread, and various flavonoids, with significant levels of bioactivities, have the potential to act as nanoformulation-based high-efficiency, cost-effective, and target-specific alternative solutions to expensive medicines. The approach appears to be viable for developing countries to combat the health challenges, especially in the high-burden cardiovascular and diabetic conditions. Furthermore, the nanomedicines, nanotech-based vaccines, and their adjuvants will potentiate the fusion of traditional herbal knowledge with modern concepts of standardization, validation, and perhaps scale-up and manufacturing of newer drugs in the nanopharmaceutical and nanomedicine domains through proper participation to maintain and promote health equity and being-well opportunity, especially in the post-COVID era to be ready, thereby also enhancing the local economic authorization.207 The technology and concept of producing nano-drugs and nanopharmaceuticals, including flavonoid-based nanotherapeutics, have the potential to overshadow traditional and conventional flavonoid dietary supplements and other flavonoid segment drugs. The nano-enabled drugs also have the potential to replace the standardized and currently used non-nanoformulated drugs with the nano-formats of the drugs, which may usher in a new pharmaceutical boom. Conclusions The advances in nanotechnology-substantiated delivery of flavonoids have amply established significant improvements in the aqueous solubility of insoluble flavonoids and flavonoid-rich extracts. The improved therapeutic efficiency, increased onsite drug bioavailability, targeted and quantity-controlled sustained delivery, and improvements in the bioaction of these natural products, particularly in addressing the health challenges of situations such as pandemics, are significant and impressive. Notwithstanding flavonoids’ antioxidant, anti-inflammatory, antiviral, antibacterial, and immunostimulant activities, their direct therapeutic use is limited by poor aqueous solubility, low GIT absorption, less transitional stability, lower bioavailability, and rapid degradation. Various preparative techniques of synthetic transformation, molecular conjugation, and nanotechnical formulation methods have overcome these limitations. The facilitated metal and organics coordination, binding imperative and desirable synthetic scaffold materials, and well-defined delivery protocols have provided passage for efficient onsite targeting of flavonoids. Numerous options introduced through polymeric moduli, carrier molecules, liposomes, nanoemulsions, nanocrystals, nanofibers, and polymetallic NPs have improved the approach of flavonoids’ clinical applications. The biomechanistic pathways involving scavenging of the ROS, modulation of signal transduction pathways (including NF-κB and MAPK), inhibition of viral replication, reduction of pro-inflammatory cytokine production, and enhancements of immune responses against pathogens have supported the flavonoids’ purported use during pandemics in various formats of drug delivery through oral, nasal, topical, and other routes depending on the specific requirement. However, significant challenges persist in this sector, with much research currently focused on pharmaceutical product development under in vitro conditions; the urgent need for clinical protocol development is imperative. The flavonoids’ and the flavonoid-rich extracts’ source identification and validation; bulk-scale products/payloads’ purity achievements, dosage and bioactivity confirmations (also under pandemic situations), and acute and chronic toxicity evaluations (and that’s especially for the extracts), and the final product’s preparative and bulk-formulation process developments need the necessary work focus. Further research also needs to focus on the development of each validated stage process standardization from the beginning to the end of the product preparation and scale-up, together with product verification and antiviral testing under the pandemic(s) for human use and the epidemiological study programs for pandemic preparedness under the guidelines of the respective national and international statutory and mandatory regulations. The drug manufacturing, distribution, and use requirements need to strictly adhere to the regulations, especially those of the WHO (World Health Organization) and the other pharmacopoeial and pharmaceutical safety and regulating bodies. If need be, new injunctions and guidelines shall be introduced for the smooth functionalization of the endemic/pandemic stage public health controls. Thus, the flavonoid nanoformulations, as the pandemic’s sole and multi-component drug and other intervention therapies, may provide better control over related health issues during the pandemic emergency. The procedure has the potential to offer a practical and promising complementary intervention against epidemic prevention, disease management, public health protection, personalized assistance, and rescue, consequently leading to sustainable support for future illnesses. Interdisciplinary collaboration is also viewed as essential for the successful application of these formulary products and procedures as effective healthcare practices on the evolving evidence-based research contributed through the expertise of nano- and medicinal chemists, pharmacologists, and clinicians worldwide.